首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Franc, aise (ANOCEF)
【24h】

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Franc, aise (ANOCEF)

机译:通过一线分子靶向治疗治疗的先进脊髓瘤:结果和预后因素。 法国肉瘤组的回顾性研究(GSF / Geto)和协会Des Neuro-Moycologues d'Expression Franc,Aise(Anocef)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: To assess the role of first-line Molecular Targeted Therapies (MTTs) in Advanced chordoma (AC) patients.
机译:背景:评估一线分子靶向治疗(MTTS)在先进的脊索瘤(AC)患者中的作用。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号